Upcoming Ex-Dividend Dates for CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular
Upcoming Ex-Dividend Dates: CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular will trade ex-dividend on 11/20/25, with respective dividends of $0.22, $0.88, and $0.20 scheduled for payment in December 2025.
Expected Price Adjustments: Following the ex-dividend date, shares of CenterPoint Energy, Regeneron, and LeMaitre Vascular are expected to open lower by approximately 0.55%, 0.12%, and 0.23%, respectively.
Dividend Aristocrats Contender: LeMaitre Vascular is noted as a future contender for the "Dividend Aristocrats" index, having achieved over 14 years of dividend increases.
Current Stock Performance: As of Tuesday trading, CenterPoint Energy and Regeneron shares have increased by 1.1% and 1.6%, while LeMaitre Vascular shares have decreased by 1.6%.
Trade with 70% Backtested Accuracy
Analyst Views on LMAT
About LMAT
About the author

- Investor Conference Schedule: LeMaitre Vascular will participate in five investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference on March 10, where management will present at 1:00 PM EDT to enhance the company's visibility among investors.
- Detailed Agenda: Following that, management will present at the Citizens Life Sciences Conference on March 11 at 1:40 PM, and will be available for one-on-one meetings at the Barclays Annual Global Healthcare Conference on March 12, further strengthening investor engagement.
- Virtual Forum Participation: At the KeyBanc Capital Markets Healthcare Forum on March 17, management will present virtually at 3:45 PM, showcasing the company's innovations and market potential in treating peripheral vascular disease.
- ROTH Conference Involvement: LeMaitre will also be available for one-on-one meetings and may participate in a presentation or fireside chat at the 38th Annual ROTH Conference from March 22-24, further expanding communication channels with investors.

- Stock Sale Announcement: Officer LeMaitre George intends to sell 100,000 shares of its common stock on February 26.
- Market Value: The total market value of the shares being sold is approximately $10.35 million.

- Significant Sales Growth: LeMaitre Vascular achieved a 16% sales growth in Q4 2025, with a gross margin of 71.7% and a 47% increase in operating income, indicating strong market performance and enhanced profitability.
- International Market Expansion: The company anticipates $10 million in international sales for ArteGraft in 2026, expanding direct operations to Poland as the 32nd country for direct sales, thereby strengthening its competitive position globally.
- Price Strategy Adjustment: LeMaitre announced an 8% blended price increase across its U.S. portfolio, with similar adjustments in Europe, which have been smoothly adopted by hospitals, expected to further boost revenue and profit levels.
- Optimistic Future Outlook: Management projects 2026 revenue of $280 million and adjusted EPS of $2.91, reflecting confidence in future growth despite the impact of a recent cyber incident.
- Dividend Increase: LeMaitre Vascular has declared a quarterly dividend increase from $0.20 to $0.25 per share, representing a 25% growth, which reflects the company's robust profitability and cash flow, thereby boosting investor confidence.
- Yield Metrics: The forward yield of this dividend stands at 1.09%, indicating the company's commitment to returning value to shareholders while providing an attractive option for income-seeking investors.
- Payment Schedule: The new dividend will be payable on March 26, with a record date of March 12 and an ex-dividend date also set for March 12, ensuring shareholders receive their earnings promptly and reinforcing the relationship between the company and its investors.
- Financial Health: The dividend increase aligns with LeMaitre Vascular's strong financial performance, showcasing the company's competitiveness and sustainability in the market, which is expected to attract more long-term investors' interest.
- Earnings Announcement Date: LeMaitre Vascular is set to release its Q4 earnings on February 25 after market close, with market participants keenly awaiting the results that could influence stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.66, reflecting a 34.7% year-over-year increase, indicating a sustained improvement in the company's profitability that may attract more investor interest.
- Revenue Expectations: The consensus revenue estimate is $62.82 million, representing a 12.7% year-over-year growth, showcasing the company's robust growth in the market and enhancing its competitive position in the medical device industry.
- Performance Review: Over the past year, LeMaitre Vascular has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, demonstrating financial stability and market confidence in its performance.
- Earnings Release Announcement: LeMaitre Vascular has announced that it will release its Q4 2025 financial results on February 25, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Schedule: The company plans to hold a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and outlook, aiming to bolster investor confidence in the company's future direction.
- Registration Details: All registrants will receive dial-in information and a PIN to access the live call, reflecting the company's professionalism and convenience in investor relations.
- Industry Context: LeMaitre Vascular focuses on devices and services for peripheral vascular disease, which affects over 200 million people globally, highlighting the company's significance and potential growth in the medical device market.





